FourThought Financial’s Intellia Therapeutics NTLA Stock Holding History

FourThought Financial’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2K	Sell	32 -352	-92%	-$21.8K	﹤0.01%	1349
2022 Q2	$20K	Sell	384 -7	-2%	-$355	﹤0.01%	876
2022 Q1	$28K	Buy	391 +80	+26%	+$6.78K	﹤0.01%	822
2021 Q4	$37K	Sell	311 -60	-16%	-$7.52K	﹤0.01%	761
2021 Q3	$49K	Buy	371 +311	+518%	+$47.1K	0.01%	702
2021 Q2	$9K	Hold	60	–	–	﹤0.01%	1127
2021 Q1	$4K	Sell	60 -3	-5%	-$201	﹤0.01%	1207
2020 Q4	$3K	Buy	+63	New	+$2.29K	﹤0.01%	1231

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FourThought Financial's NTLA Position: Q3 2022 in Review

FourThought Financial reduced its Intellia Therapeutics (NTLA) stake by 92% in Q3 2022, selling an estimated $21.8K and leaving 32 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1349.

FourThought Financial first reported a position in NTLA in Q4 2020 and has held it in 8 quarters since. The position peaked at $49K in Q3 2021. 320 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

FourThought Financial held 32 shares of Intellia Therapeutics worth $2K as of Q3 2022.
FourThought Financial sold 352 Intellia Therapeutics shares in Q3 2022, an estimated $21.8K.
Intellia Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1349 holding.
FourThought Financial first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Intellia Therapeutics position peaked at $49K in Q3 2021.
320 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.